{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T18:01:49Z","timestamp":1778522509290,"version":"3.51.4"},"update-to":[{"DOI":"10.1002\/14651858.cd013647","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000}}],"reference-count":90,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013647.pub2","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T03:36:00Z","timestamp":1637033760000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Siponimod for multiple sclerosis"],"prefix":"10.1002","volume":"2021","author":[{"given":"Liujiao","family":"Cao","sequence":"additional","affiliation":[{"name":"West China School of Nursing\/West China Hospital; Sichuan University; Chengdu China"},{"name":"School of Public Health, Evidence-Based Social Science Research Center; Lanzhou University; Lanzhou\u00a0 China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meixuan","family":"Li","sequence":"additional","affiliation":[{"name":"Evidence-Based Medicine Center, School of Basic Medical Sciences; Lanzhou University; Lanzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Health Research Methodology, Evidence and Impact; McMaster University; Hamilton Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peijing","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Health Statistics; West China School of Public Health and West China Fourth Hospital, Sichuan University; Chengdu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqin","family":"Wang","sequence":"additional","affiliation":[{"name":"The Michael G. DeGroote Institute for Pain Research and Care; McMaster University; Hamilton Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology; Tung Wah Group of Hospitals; Hong Kong China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongfeng","family":"Lao","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College; Lanzhou University; Lanzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijuan","family":"Li","sequence":"additional","affiliation":[{"name":"School of Public Health, Evidence-Based Social Science Research Center; Lanzhou University; Lanzhou City China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kehu","family":"Yang","sequence":"additional","affiliation":[{"name":"Evidence-Based Medicine Center, School of Basic Medical Sciences; \u00a0Lanzhou University; Lanzhou China"},{"name":"Lanzhou University Institute of Health Data Science; Lanzhou University; Lanzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ka","family":"Li","sequence":"additional","affiliation":[{"name":"West China School of Nursing \/West China Hospital; \u00a0Sichuan University; Chengdu China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,11,16]]},"reference":[{"issue":"10127","key":"10.1002\/14651858.CD013647.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD013647.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S1474-4422(13)70102-9","article-title":"Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study","volume":"12","author":"Selmaj","year":"2013","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0003|cit3","first-page":"194","article-title":"Evidence for improved myelination in patients treated with siponimod: Results from the Phase 3 EXPAND MRI Substudy","volume":"27","author":"Arnold","year":"2020","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0004|cit4","first-page":"232","article-title":"Safety and tolerability of conversion to siponimod in patients with relapsing multiple sclerosis: Interim results of the exchange study","volume":"26","author":"Bar-Or","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1212\/WNL.0000000000011275","article-title":"Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses","volume":"96","author":"Benedict","year":"2021","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0006|cit6","first-page":"S50","article-title":"Siponimod affects disability progression in patients with SPMS independent of relapse activity: results from the phase 3 EXPAND study","volume":"11","author":"Cree","year":"2019","journal-title":"PM & R : the Journal of Injury, Function, and Rehabilitation"},{"issue":"5","key":"10.1002\/14651858.CD013647.pub2-BIB0007|cit7","first-page":"265","article-title":"Secondary progressive multiple sclerosis: siponimod is more effective than placebo in a double-blind randomized phase III trial","volume":"25","author":"Diener","year":"2018","journal-title":"Psychopharmakotherapie"},{"issue":"3","key":"10.1002\/14651858.CD013647.pub2-BIB0008|cit8","first-page":"34","article-title":"Effects of siponimod on MRI outcomes in patients with secondary progressive multiple sclerosis: results of the phase 3 EXPAND study","volume":"23","author":"Fox","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"S33.007","DOI":"10.1212\/WNL.88.16_supplement.S33.007","article-title":"Safety and tolerability of siponimod in patients with secondary progressive multiple sclerosis","volume":"88 Suppl 16","author":"Fox","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD013647.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1358\/dot.2020.56.1.3091905","article-title":"Siponimod to treat secondary progressive multiple sclerosis","volume":"56","author":"Gajofatto","year":"2020","journal-title":"Drugs of Today (Barcelona, Spain : 1998)"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0011|cit11","first-page":"495","article-title":"2018-The EXPAND study results: safety and tolerability of siponimod in patients with secondary progressive multiple sclerosis","volume":"24","author":"Giovannoni","year":"2017","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0012|cit12","first-page":"235","article-title":"Sustained reduction of disability and cognitive decline with long-term siponimod treatment in patients with active SPMS: expand data up to 5 years","volume":"26","author":"Giovannoni","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0013|cit13","first-page":"380","article-title":"Efficacy of siponimod in secondary progressive multiple sclerosis patients with active disease: the EXPAND study subgroup analysis","volume":"25","author":"Gold","year":"2019","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0014|cit14","first-page":"328","article-title":"Siponimod slows physical disability progression and decline in cognitive processing speed in SPMS patients with active disease: A Post hoc analysis of the EXPAND study","volume":"27","author":"Gold","year":"2020","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0015|cit15","first-page":"P01.176","article-title":"Phase 2 BOLD extension study safety results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis","volume":"80 Suppl 7","author":"Hartung","year":"2013","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0016|cit16","first-page":"359","article-title":"Effect of Siponimod on the MSWS-12 and MSIS-29 in patients with SPMS from the EXPAND study","volume":"28","author":"Hobart","year":"2021","journal-title":"European Journal of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD013647.pub2-BIB0017|cit17","first-page":"752","article-title":"P036-siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis: Design of the phase 3 EXPAND trial","volume":"3","author":"Kappos","year":"2014","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"P3.151","DOI":"10.1212\/WNL.82.10_supplement.P3.151","article-title":"Safety and efficacy of siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis: results from dose-blinded extension phase of BOLD study","volume":"82 Suppl 10","author":"Kappos","year":"2014","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD013647.pub2-BIB0019|cit19","first-page":"927","article-title":"Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis: design of the phase 3 EXPAND trial","volume":"20","author":"Kappos","year":"2014","journal-title":"Multiple Sclerosis"},{"issue":"11","key":"10.1002\/14651858.CD013647.pub2-BIB0020|cit20","first-page":"317","article-title":"Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis (SPMS): baseline characteristics of the EXPAND study population","volume":"23","author":"Kappos","year":"2015","journal-title":"Multiple Sclerosis"},{"issue":"9","key":"10.1002\/14651858.CD013647.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1001\/jamaneurol.2016.1451","article-title":"Safety and efficacy of siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis: dose-blinded, randomized extension of the phase 2 BOLD study","volume":"73","author":"Kappos","year":"2016","journal-title":"JAMA Neurology"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"P3.084","DOI":"10.1212\/WNL.86.16_supplement.P3.084","article-title":"Baseline subgroup characteristics of EXPAND: a phase 3 study of siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis","volume":"86 Suppl 16","author":"Kappos","year":"2016","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0023|cit23","first-page":"828","article-title":"Efficacy and safety of siponimod in secondary progressive multiple sclerosis-results of the placebo controlled, double-blind, phase III EXPAND study","volume":"22","author":"Kappos","year":"2016","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"CT.002","DOI":"10.1212\/WNL.88.16_supplement.CT.002","article-title":"Efficacy of siponimod in secondary progressive multiple sclerosis: results of the phase 3 study","volume":"88 Suppl 16","author":"Kappos","year":"2017","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD013647.pub2-BIB0025|cit25","first-page":"397","article-title":"Efficacy of siponimod on disability progression in SPMS patients with and without on-study relapses","volume":"23","author":"Kappos","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0026|cit26","first-page":"337","article-title":"Long-term efficacy of siponimod treatment for up to 5 years in patients with secondary progressive multiple sclerosis: Analysis of the EXPAND extension study","volume":"27","author":"Kappos","year":"2020","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"124","DOI":"10.17116\/jnevro2021121071124","article-title":"Siponimod: a new view at the therapy of secondary progressive multiple sclerosis","volume":"121","author":"Krasnov","year":"2021","journal-title":"ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0028|cit28","first-page":"S11.005","article-title":"MRI findings of BOLD: a phase 2 dose-finding study using adaptive design and modeling methods for BAF312 in relapsing-remitting MS","volume":"78 Suppl 1","author":"Li","year":"2012","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD013647.pub2-BIB0029|cit29","first-page":"207-8","article-title":"Siponimod (BAF312) treatment leads to early MRI benefits in relapsing-remitting multiple sclerosis patients: results from a phase 2 study","volume":"18","author":"Li","year":"2012","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0030|cit30","unstructured":"Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis clinicaltrials.gov\/show\/NCT00879658 (first received 25 April 2020)"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0031|cit31","unstructured":"Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) clinicaltrials.gov\/show\/NCT01665144 (first received 25 April 2020)"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0032|cit32","first-page":"502-","article-title":"Effect of siponimod on cognitive processing speed in SPMS patients with active and non-active disease","volume":"26","author":"Penner","year":"2020","journal-title":"Multiple sclerosis journal"},{"issue":"10","key":"10.1002\/14651858.CD013647.pub2-BIB0033|cit33","first-page":"S510","article-title":"BAF312, a selective sphingosine 1-phosphate receptor modulator, effectively suppresses MRI lesion activity in relapsing-remitting multiple sclerosis: findings of an adaptive dose-ranging phase 2 study","volume":"17","author":"Selmaj","year":"2011","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0034|cit34","first-page":"S45","article-title":"The first 12 months of siponimod utilization following approval in the United States","volume":"26","author":"Shah","year":"2020","journal-title":"Journal of Managed Care and Specialty Pharmacy"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0035|cit35","first-page":"S30.001","article-title":"BAF312, a selective sphingosine-1-phosphate receptor modulator improves MRI and clinical outcomes in relapsing-remitting multiple sclerosis (RRMS)","volume":"78 Suppl 1","author":"Stuve","year":"2012","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0036|cit36","first-page":"P07.110","article-title":"Phase 2 bold extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis","volume":"80 Suppl 7","author":"Stuve","year":"2013","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"236","DOI":"10.18553\/jmcp.2020.26.3.236","article-title":"The Effectiveness and Value of Siponimod for Secondary Progressive Multiple Sclerosis","volume":"26","author":"Synnott","year":"2020","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0038|cit38","first-page":"44","article-title":"The EXPAND study results: efficacy of siponimod in secondary progressive multiple sclerosis","volume":"24","author":"Vermersch","year":"2017","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0039|cit39","first-page":"55","article-title":"Siponimod delays the time to wheelchair in patients with SPMS: results from the EXPAND study","volume":"25","author":"Vermersch","year":"2019","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0040|cit40","first-page":"478","article-title":"Effect of siponimod on grey matter atrophy in patients with secondary progressive multiple sclerosis: Subgroup analyses from the EXPAND study","volume":"27","author":"Vermersch","year":"2020","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0041|cit41","first-page":"518","article-title":"Baseline characteristics of amasia: First real world data of siponimod treated patients with secondary progressive multiple sclerosis","volume":"26","author":"Weber","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"3","key":"10.1002\/14651858.CD013647.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"e134251","DOI":"10.1172\/jci.insight.134251","article-title":"Siponimod enriches regulatory T and B lymphocytes in secondary progressive multiple sclerosis","volume":"5","author":"Wu","year":"2020","journal-title":"JCI Insight"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0043|cit43","unstructured":"A phase II, double-blind, randomized, multi-center, adaptive dose-ranging, placebo-controlled, parallel-group study evaluating safety, tolerability and efficacy on MRI lesion parameters and determining the dose response curve of BAF312 given orally once daily in patients with relapsing-remitting multiple sclerosis http:\/\/www.who.int\/trialsearch\/Trial2.aspx?id=EUCTR2008-008719-25-HU(first received 25 August 2021)"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0044|cit44","unstructured":"Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis clinicaltrials.gov\/show\/NCT01185821 (first received 25 August 2021\uff09"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0045|cit45","unstructured":"Study of efficacy, safety and tolerability data for BAF312 compared to placebo in patients with secondary progressive multiple sclerosis followed by extended treatment with BAF312 ClinicalTrials.gov\/show\/EUCTR2012-003056-36-SK (first received 25 August 2020)"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0046|cit46","unstructured":"Managed Access Program (MAP) for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With Active Disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04540861"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0047|cit47","unstructured":"Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04593927"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0048|cit48","unstructured":"Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04925557"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0049|cit49","first-page":"279","article-title":"Siponimod (BAF312) (and\/or its metabolites) penetrates into the CNS and distributes to white matter areas","volume":"18 Suppl 4","author":"Aslanis","year":"2012","journal-title":"Multiple Sclerosis"},{"issue":"7454","key":"10.1002\/14651858.CD013647.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"GRADE Working Group. Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD013647.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/nan.12048","article-title":"Immunohistochemical detection of sphingosine-1-phosphate receptor1 and 5 in human multiple sclerosis lesions","volume":"40","author":"Brana","year":"2014","journal-title":"Neuropathology and Applied Neurobiology"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/j.1476-5381.2009.00451.x","article-title":"FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system","volume":"158","author":"Brinkmann","year":"2009","journal-title":"British Journal of Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD013647.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis","volume":"33","author":"Chun","year":"2010","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3389\/fimmu.2020.00635","article-title":"Siponimod (BAF312) activates Nrf2 while hampering NF\u03baB in human astrocytes, and protects from astrocyte-induced neurodegeneration","volume":"11","author":"Colombo","year":"2020","journal-title":"Frontiers In Immunology"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0055|cit55","unstructured":"Deeks JJ Higgins JP Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from www.training.cochrane.org\/handbook"},{"issue":"3","key":"10.1002\/14651858.CD013647.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"7109","key":"10.1002\/14651858.CD013647.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0058|cit58","unstructured":"Drug Approval Package: Mayzent (siponimod) www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/209884Orig1s000SumR.pdf"},{"issue":"6","key":"10.1002\/14651858.CD013647.pub2-BIB0059|cit59","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008933.pub2","article-title":"Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis","author":"Filippini","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"13","key":"10.1002\/14651858.CD013647.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12974-016-0686-4","article-title":"Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis","volume":"26","author":"Gentile","year":"2016","journal-title":"Journal of Neuroinflammation"},{"issue":"5","key":"10.1002\/14651858.CD013647.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1476-5381.2012.02061.x","article-title":"The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate","volume":"167","author":"Gergely","year":"2012","journal-title":"British Journal of Pharmacology"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0062|cit62","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT 2020"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0064|cit64","unstructured":"Higgins JP Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0065|cit65","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1742-2094-8-76","article-title":"Fingolimod modulates microglial activation to augment markers of remyelination","volume":"8","author":"Jackson","year":"2011","journal-title":"Journal of Neuroinflammation"},{"issue":"9","key":"10.1002\/14651858.CD013647.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1001\/jamaneurol.2016.1451","article-title":"Safety and efficacy of siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis: dose-blinded, randomized extension of the phase 2 BOLD Study","volume":"73","author":"Kappos","year":"2016","journal-title":"JAMA Neurology"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1177\/1352458517694432","article-title":"New insights into the burden and costs of multiple sclerosis in Europe","volume":"23","author":"Kobelt","year":"2017","journal-title":"Multiple Sclerosis"},{"issue":"11","key":"10.1002\/14651858.CD013647.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD013647.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD013647.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD013647.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"183-93","DOI":"10.1016\/S1474-4422(14)70256-X","article-title":"Pathological mechanisms in progressive multiple sclerosis","volume":"14","author":"Mahad","year":"2015","journal-title":"Lancet Neurology"},{"issue":"1","key":"10.1002\/14651858.CD013647.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Annals of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD013647.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013647.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"42","DOI":"10.7224\/1537-2073.2016-062","article-title":"A framework of care in multiple sclerosis, part 2: symptomatic care and beyond","volume":"19","author":"Newsome","year":"2017","journal-title":"International Journal of MS Care"},{"issue":"10","key":"10.1002\/14651858.CD013647.pub2-BIB0076|cit76","first-page":"438","article-title":"The S1P1\/S1P5 receptor modulator BAF312 reverses neurological deficits in ongoing EAE, reduces specific lymphocyte subsets in healthy volunteers and is a potential new multiple sclerosis treatment","volume":"15","author":"Nuesslein-Hildesheim","year":"2009","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S1474-4422(06)70581-6","article-title":"Sex ratio of multiple sclerosis in Canada: a longitudinal study","volume":"5","author":"Orton","year":"2006","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0078|cit78","unstructured":"Page MJ Higgins JP Sterne JA Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated February 2021). Cochrane, 2021 Available from www.training.cochrane.org\/handbook"},{"issue":"2","key":"10.1002\/14651858.CD013647.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Annals of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD013647.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD013647.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"169-80","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0082|cit82","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2020"},{"issue":"12","key":"10.1002\/14651858.CD013647.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1177\/1352458518799580","article-title":"Symptomatology and symptomatic treatment in multiple sclerosis: results from a nationwide MS registry","volume":"25","author":"Rommer","year":"2019","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/jnnp-2012-304333","article-title":"Onset of secondary progressive phase and long-term evolution of multiple sclerosis","volume":"85","author":"Scalfari","year":"2014","journal-title":"Journal of Neurology Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0085|cit85","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated February 2021). Cochrane, 2021 Available from www.training.cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD013647.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40263-020-00785-7","article-title":"Siponimod: a review in secondary progressive multiple sclerosis","volume":"35","author":"Scott","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1002\/14651858.CD013647.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"2489-505","DOI":"10.1016\/j.clinthera.2015.09.006","article-title":"Effects of therapeutic and supra therapeutic doses of siponimod (BAF312) on cardiac repolarization in healthy subjects","volume":"37","author":"Shakeri-Nejad","year":"2015","journal-title":"Clinical Therapeutics"},{"issue":"10130","key":"10.1002\/14651858.CD013647.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1622-36","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD013647.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurology"},{"issue":"6","key":"10.1002\/14651858.CD013647.pub2-BIB0090|cit90","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013647","article-title":"Siponimod for multiple sclerosis","author":"Cao","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T06:57:09Z","timestamp":1726124229000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013647.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,11,16]]},"references-count":90,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013647.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,16]]}}}